InnoCare Pharma (SHSE:688428) ROCE %: 16.07% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688428 InnoCare Pharma Ltd SHSE:688428
79 GF Score
Price ¥29.60
GF Value ¥34.11
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma ROCE %?

InnoCare Pharma SHSE:688428 -7.21% 79 ROCE % is 16.07% as of Dec. 2025. GuruFocus rates SHSE:688428 with a GF Score™ of 79/100 and a GF Value™ of ¥34.11 (Modestly Undervalued). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InnoCare Pharma's annualized ROCE % for the quarter that ended in Dec. 2025 was 16.07%.

InnoCare Pharma  (SHSE:688428) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InnoCare Pharma ROCE % Related Terms

InnoCare Pharma ROCE % Historical Data

* Premium members only.

The historical data trend for InnoCare Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma ROCE % Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -0.30 -11.45 -7.58 -5.18 7.99

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.03 -6.69 -4.06 -0.08 16.07
SHSE:688428
79GF Score
InnoCare Pharma Ltd SHSE:688428
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCare Pharma ROCE % Calculation

InnoCare Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=709.872/( ( (9407.494 - 1061.004) + (10823.6 - 1397.78) )/ 2 )
=709.872/( (8346.49+9425.82)/ 2 )
=709.872/8886.155
=7.99 %

InnoCare Pharma's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1426.47/( ( (9363.534 - 1035.737) + (10823.6 - 1397.78) )/ 2 )
=1426.47/( ( 8327.797 + 9425.82 )/ 2 )
=1426.47/8876.8085
=16.07 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.07% mean?
InnoCare Pharma (SHSE:688428) has a ROCE % of 16.07% as of Dec. 2025.
Is InnoCare Pharma's ROCE % too high?
InnoCare Pharma's current ROCE % is 16.07%. Overall, InnoCare Pharma has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's ROCE % compare to VRTX and REGN?
InnoCare Pharma's ROCE % of 16.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. InnoCare Pharma's current ROCE % is 16.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (SHSE:688428) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥34.11, compared to a current price of ¥29.60 — trading 13.2% below its estimated fair value. The current ROCE % is 16.07%. InnoCare Pharma's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For InnoCare Pharma (SHSE:688428), the current ROCE % is 16.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (SHSE:688428) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of ¥29.60 is trading 13.2% below its estimated GF Value™ of ¥34.11. GuruFocus considers InnoCare Pharma to be Modestly Undervalued.

Key valuation signals for SHSE:688428:

  • ROCE %: 16.07%
  • GF Value™: ¥34.11 vs. price of ¥29.60 (13.2% below fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688428 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCare Pharma Business Description

Other Exchanges 09969:Hong Kong33C:Germany
Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
79GF Score

Get the complete analysis for SHSE:688428

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥29.60
Price
¥34.11
GF Value